Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Clinical trials sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd., explained in plain language.
-
New injection shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new drug called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have a condition called secondary hyperparathyroidism (high parathyroid hormone). The goal was to see if the drug could safely lower hormone levels by at least 30%. Partic…
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise for dialysis patients with hormone disorder
Disease control CompletedThis study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower these hormone levels. Participants received either t…
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Tiny trial tracks new Drug's journey in dialysis patients
Knowledge-focused CompletedThis early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool …
Phase: PHASE1 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC